ChromaDex Corporation – Consensus Indicates Potential 70.3% Upside

Broker Ratings

ChromaDex Corporation found using ticker (CDXC) now have 5 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 9 and 7 calculating the average target price we see 7.9. With the stocks previous close at 4.64 this now indicates there is a potential upside of 70.3%. There is a 50 day moving average of 4.95 and the 200 day moving average is 4.84. The company has a market capitalisation of $285m. Find out more information at:

ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is headquartered in Los Angeles, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index